Key result
Aspirin therapy after a first ischemic stroke in patients with end-stage renal disease on dialysis was associated with a reduced risk of death and stroke readmission (HR 0.671; P<0.001).
Why the study?
Does antiplatelet therapy reduce death and readmission for stroke in end-stage renal disease patients undergoing dialysis after a first ischemic stroke?
Population
1936 patients with end-stage renal disease undergoing dialysis who experienced a first ischemic stroke…
Design
Cohort
Follow-up
11 years
Authors
Loading...
May support aspirin for secondary prevention after ischemic stroke in dialysis patients; extends observational data but requires prospective RCTs.
Cohort (n=1,936)
Does antiplatelet therapy reduce death and readmission for stroke in end-stage renal disease patients undergoing dialysis after a first ischemic stroke?
Hazard Ratio: 0.671
p-value: p=<0.001
Aspirin therapy appears safe and effective for secondary prevention of ischemic stroke in patients with end-stage renal disease on dialysis, significantly reducing the composite of death and stroke readmission without significantly increasing bleeding.
Chen et al. (2014) conducted a cohort in First-time ischemic stroke in end-stage renal disease patients undergoing dialysis (n=1,936). Antiplatelet therapy (aspirin or clopidogrel) vs. No antiplatelet therapy (implied) was evaluated on Death and readmission to hospital for stroke (HR 0.671, p=<0.001). Aspirin therapy after a first ischemic stroke in patients with end-stage renal disease on dialysis was associated with a reduced risk of death and stroke readmission (HR 0.671; P<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: